October 1991

Clinical Implications of the Competitive Inhibition of the Debrisoquin-Metabolizing Isozyme by Quinidine

Author Affiliations

From the Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Md.

Arch Intern Med. 1991;151(10):1985-1992. doi:10.1001/archinte.1991.00400100065011

Approximately 10% of western populations are genetically deficient in the enzyme that metabolizes the antihypertensive drug debrisoquin. These "poor metabolizers" process many common medications in an aberrant fashion, resulting in a variety of untoward consequences including exaggerated drug effect, subtherapeutic drug concentrations, or complex drug interactions. A variety of medications, including neuroleptics, antidepressants, β-blockers, and certain antiarrhythmics, are subject to the influence of this metabolic polymorphism. Quinidine administration changes persons to poor metabolizers of debrisoquin for the duration of therapy. Thus, the use of quinidine with any of the other drugs metabolized by this isozyme may be expected to result in a drug interaction in which a person's response will mimic that of a poor metabolizer. Because no test is commonly available to determine directly the debrisoquin metabolic phenotype, clinicians should be alert to unusual drug reactions in patients receiving quinidine concurrently with the other medications.

(Arch Intern Med. 1991;151:1985-1992)